(NASDAQ: ALNY) Alnylam Pharmaceuticals's forecast annual revenue growth rate of 37.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 118.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.25%.
Alnylam Pharmaceuticals's revenue in 2026 is $3,210,070,000.On average, 32 Wall Street analysts forecast ALNY's revenue for 2026 to be $730,457,299,722, with the lowest ALNY revenue forecast at $606,930,879,892, and the highest ALNY revenue forecast at $845,396,321,382. On average, 26 Wall Street analysts forecast ALNY's revenue for 2027 to be $937,083,311,074, with the lowest ALNY revenue forecast at $755,162,583,688, and the highest ALNY revenue forecast at $1,089,542,657,046.
In 2028, ALNY is forecast to generate $1,088,485,746,502 in revenue, with the lowest revenue forecast at $865,213,394,082 and the highest revenue forecast at $1,375,436,959,198.